Intake of energy is best predicted by overeating tendency and consumption of fat is best predicted by dietary restraint: A 4-year follow-up of patients with newly diagnosed Type 2 diabetes

Appetite ◽  
2008 ◽  
Vol 50 (2-3) ◽  
pp. 544-547 ◽  
Author(s):  
Tatjana Van Strien ◽  
Floris A. Van de Laar
Keyword(s):  
Type 2 Diabetes ◽  
Dietary Restraint ◽  
Newly Diagnosed

scholarly journals Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

2018 ◽  
Vol 5 (2) ◽  
pp. 424
Author(s):  
Pradeep V. Gadge ◽  
Roshani P. Gadge ◽  
Nikita D. Paralkar
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Retrospective Study ◽  
Blood Sugar ◽  
Therapeutic Effectiveness ◽  
Glycemic Response ◽  
Newly Diagnosed ◽  
Long Duration

Background: Teneligliptin was recently approved for type 2 diabetes (T2D) management in India and is used as monotherapy or in combination with different antidiabetic drugs. The aim of this study was to identify patients’ characteristics associated with better glycemic response to teneligliptin and metformin.Methods: A retrospective analysis of data was performed in patients of T2D with HbA1c above 7% who were treated with teneligliptin 20 mg/d as add on to metformin (500-100 mg/d) and whose follow-up data at 12-weeks was available. Fasting blood sugar (FBS) and post-prandial blood sugar (PPBS) changes were analysed.  Results: Among 66 patients included in analysis, mean age was 61.0±9.8 years and 53% were females. Median duration of diabetes was 2 years. At 12-weeks, a significant reduction PPBS was observed (mean change: -14.3 mg/dL, p=0.009) but not in FBS (mean change: -2.4 mg/dL, p=0.353). Among different patients’ characteristics, age ≤60 years (p=0.006), duration of ≤1 year (p=0.023), body-mass index ≥25 kg/m2 (p=0.009), presence of dyslipidemia (p=0.05) and absence of complications (p=0.012) were associated with significant reduction in PPBS but not in FBS.Conclusions: A younger, newly-diagnosed, obese T2D patients with dyslipidemia without any complications of diabetes can derive better therapeutic effectiveness from teneligliptin added to metformin. These findings need to be confirmed in large, prospective, long duration study.  

scholarly journals Health Care Utilization Following Newly-Diagnosed Type-2 Diabetes in Sweden: A Follow-Up of 38,956 Patients in a Real Clinical Setting

2013 ◽  
Vol 16 (7) ◽  
pp. A451
Author(s):  
U. Sabale ◽  
J. Bodegård ◽  
J. Sundström ◽  
B. Svennblad ◽  
C.J. Östgren ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Care ◽  
Health Care Utilization ◽  
Clinical Setting ◽  
Care Utilization ◽  
Newly Diagnosed

scholarly journals Phenotyping Individuals With Newly-Diagnosed Type 2 Diabetes at Risk for All-Cause Mortality: A Single Centre Observational, Prospective Study

2020 ◽  
Author(s):  
Edoardo Biancalana ◽  
Federico Parolini ◽  
Alessandro Mengozzi ◽  
Anna Solini
Keyword(s):  
Type 2 Diabetes ◽  
Mortality Rate ◽  
Disease Duration ◽  
Previous History ◽  
Newly Diagnosed ◽  
Time Data ◽  
Short Disease Duration ◽  
All Cause Mortality

Abstract Background Type 2 diabetes (T2D) shows a high mortality rate, dependent on disease duration, comorbidities and glucose control over time. Data on patients with short disease duration are scanty.Methods We prospectively followed a cohort of newly-diagnosed T2D patients referring to a single diabetes centre, treated according to the international guidelines and checked every 6-12 months. All-cause mortality and major cardiovascular (CV) events were registered.Results 289 patients out of 3019 consecutive first attendances matched inclusion criteria and were included in the observation. Mean follow-up was 51.2 months. At 31 December 2018, 253 patients were alive and 36 deceased. At baseline, deceased individuals were older, with lower eGFR and lower uric acid, higher prevalence of atrial fibrillation. During the follow-up, 18 non-fatal CV events were adjudicated; patients with incident CV disease (CVD) differed at baseline for sex, previous history of CVD and retinopathy, higher use of secretagogues and lower use of metformin. At multivariate analysis, age and previous CVD were the only independent determinants of all-cause mortality and incident CVD, respectively. In deceased individuals, eGFR slope was markedly unstable and ΔeGFR at the end of the follow-up was higher (p<0.001), and predicted mortality. Conclusion Newly-diagnosed T2D patients followed according to the best clinical practice show a mortality rate similar to that reported in more complicated patients with longer disease duration; none of the clinical and biochemical variables commonly measured at baseline can predict mortality or incident CVD; early metformin use seems to be associated with no risk of prevalent or incident retinopathy.

scholarly journals Phenotyping Individuals With Newly-Diagnosed Type 2 Diabetes at Risk for All-Cause Mortality: A Single Centre Observational, Prospective Study

2020 ◽  
Author(s):  
Edoardo Biancalana ◽  
Federico Parolini ◽  
Alessandro Mengozzi ◽  
Anna Solini
Keyword(s):  
Type 2 Diabetes ◽  
Mortality Rate ◽  
Disease Duration ◽  
Previous History ◽  
Newly Diagnosed ◽  
Time Data ◽  
Short Disease Duration ◽  
All Cause Mortality

Abstract Background Type 2 diabetes (T2D) shows a high mortality rate, dependent on disease duration, comorbidities and glucose control over time. Data on patients with short disease duration are scanty. Methods We prospectively followed a cohort of newly-diagnosed T2D patients referring to a single diabetes centre, treated according to the international guidelines and checked every 6-12 months. All-cause mortality and major cardiovascular (CV) events were registered. Results 289 patients out of 3019 consecutive first attendances matched inclusion criteria and were included in the observation. Mean follow-up was 51.2 months. At 31 December 2018, 253 patients were alive and 36 deceased. At baseline, deceased individuals were older, with lower eGFR and lower uric acid, higher prevalence of atrial fibrillation. During the follow-up, 18 non-fatal CV events were adjudicated; patients with incident CV disease (CVD) differed at baseline for sex, previous history of CVD and retinopathy, higher use of secretagogues and lower use of metformin. At multivariate analysis, age and previous CVD were the only independent determinants of all-cause mortality and incident CVD, respectively. In deceased individuals, eGFR slope was markedly unstable and ΔeGFR at the end of the follow-up was higher (p<0.001), and predicted mortality. Conclusion Newly-diagnosed T2D patients followed according to the best clinical practice show a mortality rate similar to that reported in more complicated patients with longer disease duration; none of the clinical and biochemical variables commonly measured at baseline can predict mortality or incident CVD; early metformin use seems to be associated with no risk of prevalent or incident retinopathy.

scholarly journals Plasma phospholipid EPA and DHA are divergently associated with overall mortality in newly diagnosed diabetic patients: results from a follow-up of the Nord-Trøndelag Health (HUNT) Study, Norway

2013 ◽  
Vol 2 ◽  
Author(s):  
Morten Lindberg ◽  
Arne Åsberg ◽  
Kristian Midthjell ◽  
Kristian S. Bjerve
Keyword(s):  
Type 2 Diabetes ◽  
Total Mortality ◽  
Plasma Phospholipid ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Negatively Associated ◽  
Epa And Dha ◽  
Hunt Study

AbstractData concerning the long-term effects of n-3 and n-6 PUFA on disease control and development of complications in diabetic patients are inconsistent. The relationship between plasma phospholipid PUFA and total mortality in type 2 diabetes is unknown. The present study aims to investigate the association between plasma phospholipid fatty acid relative concentrations expressed as weight percentage and total mortality in patients with type 2 diabetes. Mortality rates were evaluated at 5, 10, 15 and 20 years in patients with newly diagnosed diabetes (n 323) and matched non-diabetic controls (n 200) recruited from the Nord-Trøndelag Health (HUNT) Study, Norway. Kaplan–Meier survival curves were constructed and Cox regression analysis was used to calculate hazard ratios (HR) adjusted for biochemical and clinical covariates. After 10 years of follow-up, EPA in the diabetic population was negatively associated with total mortality, with an HR at the fifth quintile of 0·47 (95 % CI 0·25, 0·90) compared with the first quintile. In contrast, DHA was positively associated with total mortality, with an HR at the fifth quintile of 2·87 (95 % CI 1·45, 5·66). Neither EPA nor DHA was associated with total mortality in matched non-diabetic controls. In conclusion, plasma phospholipid relative concentrations of EPA were negatively associated, while those of DHA were positively associated with total mortality in diabetics. This difference in associations suggests a differential effect of EPA and DHA in patients with type 2 diabetes.

Effectiveness of family involvement in newly diagnosed type 2 diabetes patients: a follow-up study

2016 ◽  
Vol 99 (5) ◽  
pp. 776-782 ◽  
Author(s):  
Mai Shi ◽  
Mei-Yan Xu ◽  
Zhao-Lan Liu ◽  
Xue-Ying Duan ◽  
Yan-Bo Zhu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Family Involvement ◽  
Newly Diagnosed ◽  
Follow Up Study ◽  
Diabetes Patients

scholarly journals Impact of Novel Guidelines on Multifactorial Control and Its Association with Mortality in Adult Patients with Hypertension and Newly Diagnosed Type 2 Diabetes: A 4-Year Prospective Multicenter Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Ngoc-Thanh-Van Nguyen ◽  
Hoa Ngoc Chau ◽  
Nam Hoai Le ◽  
Hai Hoang Nguyen ◽  
Hoai-An Nguyen
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
High Risk ◽  
Newly Diagnosed ◽  
Hypertensive Patients ◽  
Simultaneous Control ◽  
Diagnosed Diabetes ◽  
Newly Diagnosed Diabetes

Background and Rationales. Hypertensive patients with newly diagnosed diabetes are associated with heightened risks for cardiovascular events. Yet endorsement of state-of-the-art guidelines with more stringent goals poses significant challenges in obtaining multifactorial control. This study aimed to illustrate the impact of novel targets on achieving simultaneous control overtime and its association with mortality. Methods. This prospective, observational study involved adult hypertensive patients with newly diagnosed type 2 diabetes mellitus at two university hospitals in Vietnam. The median time of follow-up was 4 years (August 2016–August 2020). The primary outcome was time to all-cause mortality. Results. 246 patients were included with a mean age of 64.5 ± 10.4. 58.5% were females. 64.2% were categorized as high risk. At baseline, ischemic heart disease, dyslipidemia, and chronic kidney disease (CKD) were present in 54.9%, 67.1%, and 41.1% of patients. Renin–angiotensin–aldosterone inhibitor, metformin, and statin were prescribed in 89.8%, 66.3%, and 67.1%. Among three risk factors, LDL-c control was the hardest to achieve, increasing from 5.7% to 8.5%. In contrast, blood pressure control decreased from 56.1% in 2016 to 30.2% in 2020, when the second wave of COVID-19 hit our nation. While contemporary targets resulted in persistently low simultaneous control at 1.2%, significant improvement was observed with conventional criteria (blood pressure  < 140/90 mmHg, HbA1c < 7%, LDL-c < 70 mg/dl), increasing from 14.6% to 33.7%. During follow-up, the mortality rate was 24.4 events per 1000 patient-years, exclusively in patients with early newly diagnosed diabetes. Improving control overtime, not at baseline, was associated with less mortality. Conversely, age >75 years (HR = 2.6) and CKD (HR = 4.9) were associated with increased mortality. Conclusion. These findings demonstrated real-world difficulties in managing hypertension and newly diagnosed diabetes, especially with stringent criteria from novel guidelines. High-risk profile, high mortality, and poor simultaneous control warrant more aggressive cardiorenal protection, focusing more on aging CKD patients with early newly diagnosed diabetes.

scholarly journals A 12-year follow-up study of all-cause and cardiovascular mortality among 10 532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland

2010 ◽  
Vol 27 (10) ◽  
pp. 1124-1129 ◽  
Author(s):  
K. N. Barnett ◽  
S. A. Ogston ◽  
M. E. T. McMurdo ◽  
A. D. Morris ◽  
J. M. M. Evans
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Mortality ◽  
Newly Diagnosed ◽  
Follow Up Study

scholarly journals Occurrence of comorbidities in newly diagnosed type 2 diabetes patients and their impact after 11 years’ follow-up

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sophia Eilat-Tsanani ◽  
Avital Margalit ◽  
Liran Nevet Golan
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Management ◽  
Newly Diagnosed ◽  
Risk Of Death ◽  
High Prevalence ◽  
Long Term Follow Up ◽  
New Onset

AbstractThe burden of type 2 diabetes is growing, not only through increased incidence, but also through its comorbidities. Concordant comorbidities for type 2 diabetes, such as cardiovascular diseases, are considered expected outcomes of the disease or disease complications, while discordant comorbidities are not considered to be directly related to type 2 diabetes and are less extensively addressed under diabetes management. Here we show that the combination of concordant and discordant comorbidities appears frequently in persons with diabetes (75%). Persons with combined comorbidities visited family physicians more than persons with discordant, concordant or no comorbidity (17.3 ± 10.2, 11.6 ± 6.5, 8.7 ± 6.8, 6.3 ± 6.6 visits/person/year respectively, p < 0.0001). The risk of death during the study period was highest in persons with combined comorbidities and discordant only comorbidities (HR = 33.4; 95% CI 12.5–89.2 and HR = 33.5; 95% CI 11.7–95.8), emphasizing the contribution of discordant comorbidities to the outcome. Our study is unique as a long-term follow-up of an 11-year cohort of 9725 persons with new-onset type 2 diabetes. The findings highlight the contribution of discordant comorbidity to the burden of the disease. The high prevalence of the combination of both concordant and discordant comorbidities, and their appearance before the onset of type 2 diabetes, indicates a continuum of morbidity.

Sign in / Sign up

Export Citation Format

Share Document